Multidisciplinary considerations in the treatment of triple‐negative breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Multidisciplinary considerations in the treatment of triple‐negative breast cancer

Published:2020-09-28 Issue:6 Volume:70 Page:432-442
ISSN:0007-9235
Container-title:CA: A Cancer Journal for Clinicians
language:en
Short-container-title:CA A Cancer J. Clin.

Author:

Bellon Jennifer R.¹²³,Burstein Harold J.²³,Frank Elizabeth S.²,Mittendorf Elizabeth A.²³⁴,King Tari A.²³⁴^ORCID

Affiliation:

1. Department of Radiation Oncology Dana‐Farber Cancer Institute and Brigham and Women's Hospital Boston Massachusetts

2. Breast Oncology Program Dana‐Farber/Brigham and Women's Cancer Center Boston Massachusetts

3. Harvard Medical School Boston Massachusetts

4. Division of Breast Surgery Department of Surgery Brigham and Women's Hospital Boston Massachusetts

Publisher

Wiley

Subject

Oncology,Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.3322/caac.21643

Reference59 articles.

1. AJCC Cancer Staging Manual

2. Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

3. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

4. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

5. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterations;World Journal of Surgical Oncology;2024-09-12

2. The expression and role of the Lem-D proteins Ankle2, Emerin, Lemd2, and TMPO in triple-negative breast cancer cell growth;Frontiers in Oncology;2024-04-24

3. Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study;Nature Communications;2024-03-27

4. Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study;2023-12-04

5. Combined Molecular and Morphological Imaging of CTCs for HER2-Targeted Chemotherapy Guidance;Analytical Chemistry;2023-08-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3